Marea Therapeutics
Tracked across 1 events · 6 articles · First seen Sep 17, 2026 · Last active Sep 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Lisata Therapeutics acquired Marea Therapeutics, a clinical-stage biotechnology company developing next-generation medicines for cardioendocrine diseases, in a stock-for-stock transaction. All of Marea's outstanding equity interests were exchanged for 1,793,129 shares of Lisata common stock and…
Impact: Target whose equity holders receive about 59.54% of the combined company, giving its cardioendocrine pipeline MAR001/005 and MAR002 a funded path to pivotal data.
Sep 17, 2026 · 6 articles
20
Leerink Partners advised on acquisition Marea TherapeuticsLisata Acquires Marea,...
ERGEN INTELLIGENCE
Track Marea Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard